The FDA released briefing documents related to Tuesday's meeting of the Antimicrobial Drugs Advisory Committee, which will take up the NDA for tecovirimat, sponsored by Siga Technologies Inc., of New York, for the treatment of smallpox disease caused by variola virus in adults and pediatric patients.